Last reviewed · How we verify
NCT06560112
An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
Phase 2 trial testing AK104 in Recurrent Ovarian Cancer in 172 participants. Currently enrolling.
1 May 2026
Quick facts
| Lead sponsor | Akeso |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 172 |
| Start date | 12 November 2024 |
| Primary completion | 1 May 2026 |
| Estimated completion | 1 May 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- AK104 — full drug profile →
- AK112 — full drug profile →
- Chemotherapy (chemotherapy) — full drug profile →
Conditions studied
- Recurrent Ovarian Cancer — all drugs for Recurrent Ovarian Cancer →
Sponsor
Akeso — full company profile →
Who can join
18 and older, female only, with Recurrent Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Genetic and therapeutic heterogeneity shape the baseline and longitudinal immune ecosystem of ovarian clear cell carcinoma.
Xia S, Chen L, Yu M, Li J, et al · · 2024 · cited 13× · PMID 39608974 · DOI 10.1136/jitc-2024-010069
Verify or expand the search:
- PubMed search for NCT06560112
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of AK104
Trials testing the same drug.
- NCT07052253 — A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC. · Phase 2 · recruiting
- NCT06946836 — Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Ce · Phase 2 · not yet recruiting
- NCT06542549 — Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Ad · Phase 3 · not yet recruiting
- NCT06371157 — A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With · Phase 3 · recruiting
- NCT06251388 — A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab（AK104） for Newly Diagnosed Local Advanced Cervical Cance · Phase 2 · recruiting
Other recruiting trials for Recurrent Ovarian Cancer
Currently open trials in the same condition.
- NCT06769425 — HS-10502 Combination Treatment in Patients With Advanced Solid Tumors · Phase 1 · recruiting
- NCT07495384 — Efficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Arm Pro · NA · recruiting
- NCT05610735 — Combination Therapy for Recurrent Ovarian Cancer · Phase 1, PHASE2 · recruiting
- NCT06107868 — Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer · Phase 1 · active not recruiting
- NCT05942300 — CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer · Phase 1 · recruiting
Other Akeso trials
Trials by the same sponsor.
- NCT07449780 — A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XEL · Phase 3 · not yet recruiting
- NCT07412613 — Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer · Phase 3 · not yet recruiting
- NCT07357220 — A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases · Phase 1, PHASE2 · not yet recruiting
- NCT07436234 — A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic Rhinitis · Phase 2 · not yet recruiting
- NCT07436221 — A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06560112 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Akeso
- Last refreshed: 12 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06560112.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing